Mattia L. Cremona
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545.
Journal: International journal of molecular sciences
Published: March 23, 2026
Author Correction: A deep catalogue of protein-coding variation in 983,578 individuals.
Journal: Nature
Published: January 08, 2025
Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.
Journal: Cancer treatment and research communications
Published: October 15, 2024
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.
Journal: Translational oncology
Published: February 19, 2024
A deep catalogue of protein-coding variation in 983,578 individuals.
Journal: Nature
Published: June 19, 2023
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.
Journal: Cancer biology & therapy
Published: June 16, 2023
A deep catalog of protein-coding variation in 985,830 individuals.
Journal: bioRxiv : the preprint server for biology
Published: May 22, 2023
RETRACTED: Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Journal: International journal of molecular sciences
Published: May 03, 2023
Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
Journal: Journal of neuro-oncology
Published: April 18, 2023
Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.
Journal: Cancer gene therapy
Published: April 26, 2022
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin.
Journal: Journal of personalized medicine
Published: April 25, 2022
Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression.
Journal: Cancers
Published: February 02, 2022
Last Updated: 09/26/2026